ArticleJournal of molecular histology2025
RNFT2 promotes malignancy of triple-negative breast cancer and predicts poor outcomes.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Decade-Old Atlas of TMEM (Transmembrane) Protein Family in Lung Cancer: Lessons Learnt and Future Directions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer, and has a high recurrence rate. RING finger transmembrane-domain containing protein 2 (RNFT2) is a RING-finger E3 ubiquitin ligase that exerts oncogene functions in multiple malignant tumors such as bladder cancer and gastric cancer. However, RNFT2's role in TNBC is still unclear. Here, we investigated RNFT2's function and mechanism in TNBC. RNFT2 expressions in different stages of breast cancer were evaluated using the Gene Expression Profiling Interactive Analysis database. Overall survival (OS) in TNBC patients with high RNFT2 expressions was assessed with the Kaplan-Meier plotter database. Meanwhile, RNFT2 expressions in TNBC cells and tissues were determined using Western blot and quantitative real-time PCR. The relationship between RNFT2 and TNBC patients' OS rates was examined with Kaplan-Meier curve analysis. The correlation between RNFT2 expressions and TNBC clinicopathological data was estimated by the chi-square test. Moreover, RNFT2 functions in TNBC were determined using loss-of-function assay, Cell Counting Kit-8 analysis, Transwell, and tube formation assay. Furthermore, RNFT2's mechanism in TNBC was evaluated by prediction software, dual-luciferase reporter assay, and rescue experiments. Additionally, RNFT2's roles in TNBC in vivo were identified with cell-derived xenograft, hematoxylin-eosin staining, and immunohistochemical assays. RNFT2 was elevated in breast cancer, and owned different degrees of overexpression in breast cancer at different stages. Meanwhile, OS of TNBC patients with high RNFT2 expressions was poor. Also, RNFT2 expressions were positively correlated with size, TNM stage, and lymph node metastasis of TNBC. Functionally, silencing RNFT2 repressed TNBC cell proliferation, invasion, and angiogenesis. Mechanistically, miR-211-5p targeted RNFT2, and RNFT2 was negatively regulated by miR-211-5p in TNBC cells. Rescue assays further validated that miR-211-5p overexpression restrained TNBC cell proliferation, invasion, and angiogenesis, yet these impacts were abolished after RNFT2 overexpression. Meanwhile, animal experimental data further implied that RNFT2 knockdown reduced TNBC cell proliferation in vivo. RNFT2 facilitated TNBC development and predicted its adverse outcomes.
Indexed as
Identifiers
40632345What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.